Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
Nature Biotechnology
|
September 17, 2021
Identifying transcriptional programs underlying cancer drug response with TraCe-seq
Matthew T Chang, Frances Shanahan, Thi Thu Thao Nguyen, et al.
Molecular Cancer Therapeutics
|
July 29, 2010
Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor
David Parry, Timothy Guzi, Frances Shanahan, et al.
Cell Chemical Biology
|
February 11, 2023
Ternary complex dissociation kinetics contribute to mutant-selective EGFR degradation
Scott C Rosenberg, Frances Shanahan, Sayumi Yamazoe, et al.
Cancer Cell
|
October 10, 2018
Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors
Ivana Yen, Frances Shanahan, Mark Merchant, et al.
EMBO Reports
|
May 14, 2025
NRF2 supports non-small cell lung cancer growth independently of CBP/p300-enhanced glutathione synthesis
Ryan J Conrad, James A Mondo, Mike Lingjue Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2015
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors
Adil I Daud, Michelle T Ashworth, Jonathan Strosberg, et al.
ACS Medicinal Chemistry Letters
|
May 31, 2021
Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a Pyridopyridazinone pan-RAF Kinase Inhibitor
Malcolm P Huestis, Matthew R Durk, Charles Eigenbrot, et al.
Cell Reports
|
February 9, 2022
CRAF dimerization with ARAF regulates KRAS-driven tumor growth
Avinashnarayan Venkatanarayan, Jason Liang, Ivana Yen, et al.
Journal of Medicinal Chemistry
|
March 29, 2021
Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3<i>H</i>)-quinazolinone Aryl Urea pan-RAF Kinase Inhibitor
Malcolm P Huestis, Darlene Dela Cruz, Antonio G DiPasquale, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases
Kamil Paruch, Michael P Dwyer, Carmen Alvarez, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
Nature Biotechnology
|
September 17, 2021
Identifying transcriptional programs underlying cancer drug response with TraCe-seq
Matthew T Chang, Frances Shanahan, Thi Thu Thao Nguyen, et al.
Molecular Cancer Therapeutics
|
July 29, 2010
Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor
David Parry, Timothy Guzi, Frances Shanahan, et al.
Cell Chemical Biology
|
February 11, 2023
Ternary complex dissociation kinetics contribute to mutant-selective EGFR degradation
Scott C Rosenberg, Frances Shanahan, Sayumi Yamazoe, et al.
Cancer Cell
|
October 10, 2018
Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors
Ivana Yen, Frances Shanahan, Mark Merchant, et al.
EMBO Reports
|
May 14, 2025
NRF2 supports non-small cell lung cancer growth independently of CBP/p300-enhanced glutathione synthesis
Ryan J Conrad, James A Mondo, Mike Lingjue Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2015
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors
Adil I Daud, Michelle T Ashworth, Jonathan Strosberg, et al.
ACS Medicinal Chemistry Letters
|
May 31, 2021
Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a Pyridopyridazinone pan-RAF Kinase Inhibitor
Malcolm P Huestis, Matthew R Durk, Charles Eigenbrot, et al.
Cell Reports
|
February 9, 2022
CRAF dimerization with ARAF regulates KRAS-driven tumor growth
Avinashnarayan Venkatanarayan, Jason Liang, Ivana Yen, et al.
Journal of Medicinal Chemistry
|
March 29, 2021
Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3<i>H</i>)-quinazolinone Aryl Urea pan-RAF Kinase Inhibitor
Malcolm P Huestis, Darlene Dela Cruz, Antonio G DiPasquale, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases
Kamil Paruch, Michael P Dwyer, Carmen Alvarez, et al.
Page
of 3